Views

Go back 3–5 years and ask people what the major disruptive trends in healthcare would be over the next few years and among the usual suspects: AI, personalized medicine, measurable tech, you would have surely heard the term ‘Microbiome’ thrown in for good measure. There was good reason for this excitement and huge projected potential – advances in microbiology, diagnostics (especially the information systems required to understand the power and impact our gut flora can have on our health) had recently opened new possibilities for treating a number of conditions across GI, GU, and metabolic conditions – even some cancers. A number of biotechs were also advancing the investigation of targeted Microbiome therapies, with Seres Therapeutics one of those leading the charge.

Dr. David Schwartz will be presenting at the IADC 2020 Virtual Annual Meeting on a panel titled The Use of Genetic Testing in the Courtroom.

According to FDA regulation, conventional food and dietary supplements are allowed to make three categories of claims: health claims, nutrient content claims, and structure/function claims.

In a recent webinar hosted by the FDA, Dr. Theresa M. Michele, director of the Office of Nonprescription Drugs at CDER, revealed a significant update on the generally recognized as safe and effective (GRASE) status of hundreds of Monograph ingredients.